Publications by authors named "Alexandru Cezar Stoica"
Article Synopsis
- Solid tumours often lack oxygen, making them resistant to standard treatments, but compounds like nitroimidazoles (NIs) can target these hypoxic areas effectively.
- Clinically validated nitroimidazoles Iodoazomycin arabinofuranoside (IAZA) and fluoroazomycin arabinofuranoside (FAZA) show promise in treating hypoxic cancer cells, leading to changes in cell behavior and stalling their growth.
- Research indicates that NIs bind covalently to cellular proteins, particularly affecting the activity of key enzymes, while IAZA has been found to be well tolerated in mice and causes temporary tumor growth inhibition.
Tumour hypoxia negatively impacts therapy outcomes and continues to be a major unsolved clinical problem. Nitroimidazoles are hypoxia selective compounds that become entrapped in hypoxic cells by forming drug-protein adducts. They are widely used as hypoxia diagnostics and have also shown promise as hypoxia-directed therapeutics.
View Article and Find Full Text PDF